



## Goodwin at a Glance



AmLaw Global

**50**



Global Offices

**11**



Lawyers

**1000+**



Uniquely  
collaborative “one”  
firm culture



Highly regarded  
securities,  
white collar and  
IP litigation teams

### 5 Top Ranked Transactional Practices



Real Estate



Life  
Sciences



Financial  
Institutions




Tech



Private  
Equity

# Life Sciences | “One Stop Shop” Practice



100+

LS Attorneys

70+

IPTS attorneys

50+

Advanced Degrees

20+

Regulatory Attorneys



Represent **600+ life sciences clients** with specialised sector expertise and 145+ public company clients



Diverse client base of private + public companies at all stages of growth, from start-up to Fortune 100




Substantial business experience in company formation and all types of financings, mergers, acquisitions, divestitures, spin-offs, going private transactions, leveraged buyouts and strategic alliances.



Extensive **litigation experience** in many areas including antitrust and competition, appellate, commercial, class action, IP litigation, labor and employment, securities litigation, white collar crime and government investigations, and products liability and mass torts.

# Life Sciences | Fully Integrated Practice with Unprecedented Recognition



- Dedicated Privacy + Data Security practice well-versed in HIPAA compliance and other regulatory issues
- FDA practice offers deep expertise in pre-market and post-market initiatives, agency inquiries, corporate transactions, FDA due diligence and legislative issues
- Healthcare Regulatory practice counsels life sciences clients on fraud and abuse laws, coverage and reimbursement, and a full spectrum of other healthcare regulatory matters




**"Biotechnology Law Firm of the Year"** for five years by U.S. News/Best Lawyers (2013, 2014, 2015, 2017, and 2018)



**Top 3 Most Active Law Firm** for venture-backed exits

**Top 5 Most Active Law Firm** for both Global + U.S. PE deals



**Corporate Firm of the Year**

**Finance and Transactional Deal of the Year**



**122 attorneys** recognized across **50 practices**, including Corporate/M&A; Private Equity; Buyouts & Venture Capital; Life Sciences; Investment Funds; Intellectual Property and Litigation



**#1 Law Firm** for Life Sciences issuer IPOs by offering value by IPO Vital Signs (2015 - 2018)



**"IP Practice of the Year"** for five years by Law360

# Life Sciences | Real Clients, Real Results



# Life Sciences | Select Atlas Venture Experience

M+A and

## VENTURE FINANCING

## CAPITAL MARKETS

## STRATEGIC COLLABORATIONS

**akero**

COUNSEL  
TO COMPANY

Series A Financing

**AVROBIO**

COUNSEL  
TO COMPANY

Series Seed, A and B Financing

**CADENT**  
Therapeutics

COUNSEL  
TO COMPANY

Series B Financing

**gemini**  
THERAPEUTICS

COUNSEL  
TO COMPANY

Series A and B Financing

**HotSpot Therapeutics**

COUNSEL  
TO COMPANY

Series A Financing

**Intellia**  
THERAPEUTICS

COUNSEL  
TO COMPANY

Series A and B Financing

**KYMERA**

COUNSEL  
TO COMPANY

Series A and B Financing

**magenta**  
THERAPEUTICS

COUNSEL  
TO COMPANY

Series A, B and C Financing

**NAVITOR**  
PHARMACEUTICALS

COUNSEL  
TO COMPANY

Series C Financing

**NIMBUS**  
THERAPEUTICS

COUNSEL  
TO COMPANY

Series B Financing

**OBSIDIAN**  
THERAPEUTICS

COUNSEL  
TO COMPANY

Series A Financing

**UNUM**  
THERAPEUTICS

COUNSEL  
TO COMPANY

Series B Financing

**akero**

COUNSEL  
TO ISSUER

IPO

**Alnylam**  
PHARMACEUTICALS

COUNSEL  
TO ISSUER

Follow On Offerings

**AVROBIO**

COUNSEL  
TO ISSUER

IPO and Follow-On Offerings

**bicycle**  
therapeutics

COUNSEL  
TO ISSUER

IPO

**SURFACE**  
ONCOLOGY

COUNSEL  
TO ISSUER

IPO

**Intellia**  
THERAPEUTICS

COUNSEL  
TO ISSUER

IPO, Private Placement and Follow-On offerings

**magenta**  
THERAPEUTICS

COUNSEL  
TO ISSUER

IPO

**UNUM**  
THERAPEUTICS

COUNSEL  
TO ISSUER

IPO and Follow-On Offerings

**Zafgen**

COUNSEL  
TO ISSUER

IPO and Follow-On Offerings

**Alnylam**  
PHARMACEUTICALS

Collaboration with  
Regeneron Pharmaceuticals

**delinia**

Sale to  
Celgene

**gemini**  
THERAPEUTICS

Research collaboration with  
Sanquin Blood Supply

**Intellia**  
THERAPEUTICS

Strategic collaboration  
with Novartis  
and Regeneron  
Pharmaceuticals

**KYMERA**

Strategic collaboration  
with Vertex  
Pharmaceuticals

**kyn therapeutics**

Strategic collaboration  
with Celgene

**NIMBUS**  
THERAPEUTICS

Long-term strategic  
collaboration with Celgene  
and Sale of Nimbus Apollo  
and its Acetyl-CoA  
Carboxylase inhibitor  
program to Gilead  
Biosciences

**OBSIDIAN**  
THERAPEUTICS

Strategic collaboration with  
Celgene

**SURFACE**  
ONCOLOGY

Collaboration with Novartis

**Padlock**  
THERAPEUTICS

Sale to  
Bristol-Myers Squibb

**UNUM**  
THERAPEUTICS

Strategic collaboration  
and license agreement  
with Seattle Genetics

**GOODWIN**

# Preferential Fee Arrangement for Atlas Portfolio Companies

Goodwin is proud to be in its second decade of partnering with Atlas and supporting its portfolio companies across a wide array of legal areas. We are happy to offer a special fee arrangement program developed specifically for Atlas's portfolio companies, to allow your founding teams to focus on more meaningful issues and activities.

- **General Corporate Representation:** As long as your company is private, we will provide a 10% discount off of our standard fees for all day-to-day operational and corporate legal work. We will also defer the first \$35,000 of legal fees for up to one year following formation or the closing of your first financing, whichever occurs first.
- **Corporate Formations:** We will perform corporate formation work at no charge
- **Venture Fixed Fee Program:** Fees for company-side Series A representations will be capped to \$35,000 if the standard-form NVCA documents are used and there is no founder liquidity. This does not apply to: (a) recapitalizations, reorganizations or down rounds; (b) significant IP or other extraordinary diligence (other than looking at founder's prior employer agreements); and (c) tech transfer work or spin-outs.
- **IP Initiative:** Investors may receive up to 5 hours of Goodwin attorney time, at no charge, to evaluate a potential portfolio company's IP position whether in connection with a Series A financing or pre-deal basis.
- **Board of Director Meetings:** Attend any pre-IPO and regular Board of Director meetings at no charge

Goodwin's approach to client relationships is focused on creating a strategic client partnership through a combination of risk sharing, transparency and regular communication. This approach to our relationship is reflected in our pricing model, which we view as our own investment in your company. We understand that you are running a business— and we are committed to promoting your success.